KLIC Q2: Demand recovery accelerates, but advanced packaging thesis still unproven

What happened

Kulicke & Soffa reported fiscal Q2 results that management said reflect faster-than-expected improvement in demand, with strong utilization in general semiconductor and memory tied to data center capacity, and improving conditions in traditional markets like premium smartphones. This positive surprise supports the cyclical recovery narrative underlying the base case, but the stock already trades at a high trailing multiple that embeds a significant recovery. The critical unknown remains the ramp of thermo-compression bonding (TCB) for AI and HBM, which management targets at $100M+ in FY26 but has yet to disclose meaningful revenue. While core demand momentum reduces near-term downside, the advanced packaging thesis is still unproven, and the company faces execution risks from its EA wind-down and China concentration. The news is incrementally positive but does not yet justify upgrading from our WAIT rating.

Implication

The faster recovery in core markets lowers downside risk and improves the base-case outlook, but the investment case still hinges on delivering $100M+ TCB revenue by FY26; without clear evidence, the stock remains fairly priced.

Thesis delta

The earnings call adds evidence that the cyclical recovery is on track, reducing the probability of the bear case but not enhancing the bull case, which requires a successful TCB ramp. The risk/reward remains balanced, and we need to see tangible TCB orders before moving to a more constructive stance.